Biopixlar will be launched the 6th of November 2019
New patent application regarding 3D bioprinting determines the date of the Biopixlar® launch to be 6th November 2019
Fluicell AB (publ.) (“Fluicell”) hereby announces that a new patent application has been submitted to the US Patent Office (USPTO) regarding 3D bioprinting of biological tissues, and thus can announce the launch date of the company’s product, Biopixlar®, to be the 6th of November 2019. This launch is in accordance with the company’s previously communicated objective to release Biopixlar® in Q4 2019. Biopixlar® is a new concept in bioprinting where three-dimensional biological tissue can be created with very high resolution and detail.
CEO Victoire Viannay:
“We are extremely pleased to file a new patent application, allowing us to present a date for the launch of Biopixlar. Biopixlar® is a breakthrough technology that has an amazing capacity to print detailed biological tissues, which we believe will be very useful for researchers, pharmaceutical companies, and ultimately patients. This is the result of hard and dedicated work, performed by the entire Fluicell team, and I am extremely proud and thankful for their commitment and effort”.
About 3D printing with Biopixlar®: Biopixlar® is a completely new type of high-resolution bioprinter that can create detailed, multi-cellular and complex biological tissues. Fluicell has discovered a molecular cell-binder and printing methods, which allow Biopixlar® to directly print cells in three dimensions with very high precision.
Please, watch the teaser!